Pulling SEC filings + quote and writing the call…

Acadia Healthcare Company, Inc.
Next earnings Aug 3, 2026 (after close) · consensus $0.39 EPS, $861M rev
Last earnings +2.5% on 2026-04-29
A ~$1B goodwill write-down masks still-cash-generative operations trading at 0.8x sales — cheap, but levered and burning FCF to grow.
Revenue (FY2025) $3.31B · FY2025
Acadia's headline FY2025 numbers look catastrophic — a -$1.10B net loss and -$12.16 diluted EPS versus +$256M of net income in FY2024 — but the damage is overwhelmingly a non-cash goodwill impairment, not an operational collapse. The guarantor disclosure makes this explicit: goodwill fell from $2,144M to $1,163M year over year (≈$981M write-down), which approximates the entire swing into loss. Underneath it, revenue still grew 5.0% to $3.31B, operating margin held at 17.7% (operating income $586M), and operating cash flow was positive at $132M. So the business is not unprofitable on a cash basis; the auditors and management simply concluded that prior acquisitions are worth roughly a billion dollars less than carried — a forward warning about reimbursement, occupancy, or specific market economics that the filing excerpt does not fully explain.
The more durable concern is the balance sheet and cash burn. Capex of $572M dwarfs the $132M of operating cash flow, implying roughly ~$440M of negative free cash flow funded by debt: long-term debt rose 31.5% to $2.47B, the company drew $954M on its new Revolving Facility, issued $550M of 7.375% Senior Notes (a notably higher coupon than its legacy 5.0%/5.5% notes), and equity fell 36.6% to $1.95B, pushing liabilities/equity to 1.74x. Cash is thin at $133M. This is a company leveraging up to fund de novo facility expansion (the MD&A references multiple development projects backed by letters of credit) while reported returns are deeply negative (ROE -56.6%). Revenue growth is also decelerating — +13%, +12%, +7.5%, +5.0% over the last four years — and FY2023 already produced a small loss, so the impairment is not a one-off bolt from the blue.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 29, 2026, 11:54 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $2.31B | $2.61B | $2.93B | $3.15B | $3.31B |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | $191M | $273M | -$21.7M | $256M | -$1.10B |
| Diluted EPS | $2.10 | $2.98 | -$0.24 | $2.78 | -$12.16 |
| Net margin | 8.2% | 10.5% | -0.7% | 8.1% | -33.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Other-events (Item 8.01) disclosure; no quantified financial impact specified
Annual meeting voting results: director elections and say-on-pay reported
Q1 2026: revenue still growing post-impairment, no new charge flagged
Q1 2026 earnings release issued day before the 10-Q
Leadership change (Item 5.02): executive/director departure or appointment
2026 proxy for May 6 annual meeting; routine governance/comp items
Another officer/director change disclosed (Item 5.02)
FY25 net loss $1.10B on ~$980M goodwill writedown; debt up, equity -37%
FY2025 results released: $1.10B net loss driven by goodwill impairment
Sources: SEC EDGAR (CIK 0001520697, latest 10-Q filed 2026-04-30) · EODHD · Proprietary analysis · as of 6/30/2026, 3:54:51 AM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
| 2026-06-26 | Farley Brian EVP, CLAO and Secretary | Tax | 1.37K @ $26.24 | $35.9K |
| 2026-05-06 | Fucci Michael Director | Award | 6.33K | |
| 2026-05-06 | KELLY RALPH DAVID Director | Award | 6.33K | |
| 2026-05-06 | Gregg Vicky B Director | Award | 6.33K | |
| 2026-05-06 | Bernhard Jason Director | Award | 6.33K | |
| 2026-05-06 | Bernhard Jason Director | Award | 5.12K | |
| 2026-05-06 | GRIECO WILLIAM Director | Award | 6.33K | |
| 2026-05-06 | Cancelmi Daniel J Director | Award | 6.33K | |
| 2026-05-06 | Harris Patrice A Director | Award | 6.33K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1195 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.